Precision Anti-VEGF–Releasing Endothelialized Amniotic Membrane Patches for Corneal Neovascularization

Abstract

Abstract

Corneal neovascularization (CNV) is a pathologic ingrowth of blood vessels into the normally avascular cornea that disrupts transparency and leads to visual impairment. Vascular endothelial growth factor (VEGF) is a central driver of CNV, and anti-VEGF therapies such as bevacizumab and ranibizumab have shown efficacy in reducing pathological neovessels when administered topically or subconjunctivally (1,2). Amniotic membrane (AM) transplantation has long been used to support ocular surface healing and possesses inherent antiangiogenic factors such as pigment epithelium-derived factor (PEDF), which suppress endothelial proliferation (3). Integrating anti-VEGF delivery into a bioengineered AM patch — pre-endothelialized to improve biocompatibility and provide sustained, localized release — offers a next-generation therapeutic strategy for CNV. This Perspective reviews the rationale, design considerations, translational strategy, and challenges for developing precision anti-VEGF-releasing endothelialized AM patches as advanced regenerative implants that combine tissue support with controlled angiogenic inhibition.

Keywords:

 corneal neovascularization; amniotic membrane; anti-VEGF; bevacizumab; drug-eluting patch; reendothelialization; ocular tissue engineering

1. Clinical Need and Translational Opportunity

Corneal neovascularization arises from infection, inflammation, trauma, or ischemic insults and undermines corneal clarity, increasing the risk of graft rejection after transplantation and significantly lowering visual acuity. VEGF upregulation in these settings is well documented, and blockade of VEGF activity reduces pathological vessel formation and improves outcomes in experimental and clinical settings (1,2). However, existing anti-VEGF administration methods — including topical, subconjunctival, or intrastromal delivery — are limited by rapid drug clearance, need for repeated dosing, and variable tissue penetration. Meanwhile, amniotic membrane (AM) grafts have intrinsic antiangiogenic, anti-inflammatory, and epithelial-supportive properties and are widely used in ocular surface reconstruction (3,4). Modifying AM to serve as a depot for controlled anti-VEGF release and supporting endothelialization to improve integration with host tissue can address both the pathological neovascular stimulus and the need for durable therapeutic presence on the ocular surface.

2. Anti-VEGF Biology in Corneal Neovascularization

VEGF is a pivotal mediator of angiogenesis across ocular tissues. In CNV, balance between pro- and anti-angiogenic factors is disrupted, leading to new vessel sprouting from the limbal vascular plexus into the corneal stroma. Anti-VEGF approaches — including bevacizumab, ranibizumab, and other targeted agents — have demonstrated efficacy in experimental and clinical CNV models, reducing vessel density and improving visual outcomes with acceptable safety profiles (1,2,5). Nonetheless, these therapeutic benefits are constrained by drug half-life and delivery limitations, supporting the need for sustained, localized inhibition of VEGF activity.

3. Amniotic Membrane as a Therapeutic Scaffold

Human amniotic membrane possesses an extracellular matrix rich in collagen, laminin, and integrins, which supports epithelial cell attachment and migration, and its basement membrane promotes epithelial healing while suppressing inflammation. Notably, AM contains antiangiogenic proteins such as pigment epithelium-derived factor (PEDF), which directly inhibits endothelial cell proliferation and contributes to the natural antiangiogenic privilege of the cornea (3). Clinical and animal studies have shown that AM transplantation can reduce CNV, likely due to both mechanical coverage and bioactive factor release, although these effects are transient and dependent on membrane preservation and integration.

4. Precision Drug-Eluting Patch Design

A precision anti-VEGF-releasing AM patch would combine three core elements:

4.1 Sustained anti-VEGF release: AM can be incubated or engineered to incorporate anti-VEGF agents (e.g., bevacizumab) that elute over time directly at the ocular surface; in vitro studies have shown that bevacizumab bound to AM retains VEGF-blocking activity for sustained durations (4).

4.2 Endothelialization: Seeding endothelial or supportive cells onto the AM scaffold before implantation may enhance biocompatibility, reduce fibrosis, and promote integration, while facilitating controlled modulation of angiogenic cues.

4.3 Controlled degradation and residence: Engineering the patch structure to balance residence time with degradation will optimize therapeutic exposure, mechanical stability, and eventual tissue remodeling.

5. Preclinical Evaluation Roadmap

In vitro: Characterize anti-VEGF loading, release kinetics, and functional VEGF inhibition using endothelial proliferation assays and corneal keratocyte cultures.

Small animal models: Evaluate CNV inhibition, patch adhesion, and biocompatibility in established alkali burn or suture-induced neovascularization models.

Large animal models: Validate scaled patch designs in species with ocular anatomy closer to humans, assessing vision outcomes, inflammation, and sustained efficacy.

6. Clinical Translation Considerations

Regulatory strategies must address combination product classification (biologic scaffold + drug release implant), sterility and preservative standards, and ocular safety endpoints. Early clinical trials should prioritize safety and pharmacodynamics, with CNV area reduction and visual acuity improvements as primary efficacy measures. Hybrid delivery strategies (e.g., repeat patch application vs. single implant) may be explored based on release profiles and clinical needs.

7. Challenges and Future Directions

Key challenges include optimizing anti-VEGF loading capacity without compromising scaffold integrity, ensuring predictable release profiles in ocular tear dynamics, and minimizing immunogenicity from endothelialized components. Future innovations may integrate biosensors that modulate release in response to local VEGF levels or combine anti-VEGF delivery with anti-inflammatory or anti-fibrotic agents to address multifactorial drivers of CNV.

8. Conclusion

Precision anti-VEGF-releasing endothelialized amniotic membrane patches represent a promising next step in CNV therapy by merging biologically active scaffolds with controlled molecular inhibition of angiogenesis. By addressing the limitations of current anti-VEGF delivery and harnessing the regenerative potential of AM, this platform could reduce the burden of pathological corneal neovascularization and improve long-term visual outcomes.